Q2 2023 EPS Estimates for Axsome Therapeutics, Inc. Raised by Analyst (NASDAQ:AXSM)

Posted by Defense World Staff on Jul 20th, 2023

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) – Analysts at HC Wainwright boosted their Q2 2023 EPS estimates for shares of Axsome Therapeutics in a research report issued to clients and investors on Monday, July 17th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($1.48) per share for the quarter, up from their previous forecast of ($1.54). The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($3.70) per share. HC Wainwright also issued estimates for Axsome Therapeutics’ Q3 2023 earnings at ($1.29) EPS, Q4 2023 earnings at ($1.26) EPS, FY2023 earnings at ($4.31) EPS, Q1 2024 earnings at ($1.10) EPS, Q2 2024 earnings at ($0.78) EPS, Q3 2024 earnings at ($0.39) EPS, Q4 2024 earnings at $0.32 EPS and FY2024 earnings at ($1.95) EPS.

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last announced its quarterly earnings data on Monday, May 8th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($1.13) by $0.91. The business had revenue of $94.58 million for the quarter, compared to analyst estimates of $26.87 million. Axsome Therapeutics had a negative net margin of 109.75% and a negative return on equity of 152.04%.

Other equities analysts also recently issued research reports about the stock. Mizuho boosted their price target on shares of Axsome Therapeutics from $84.00 to $95.00 in a report on Thursday, May 11th. StockNews.com upgraded shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, May 11th. Morgan Stanley increased their price target on shares of Axsome Therapeutics from $83.00 to $87.00 in a research note on Tuesday, May 9th. VNET Group reissued a “reiterates” rating on shares of Axsome Therapeutics in a report on Thursday, June 22nd. Finally, Guggenheim raised their price objective on shares of Axsome Therapeutics from $90.00 to $100.00 in a report on Tuesday, May 9th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $102.92.

Axsome Therapeutics Stock Up 0.1 %

Shares of NASDAQ:AXSM opened at $74.24 on Wednesday. The company has a quick ratio of 2.95, a current ratio of 3.02 and a debt-to-equity ratio of 1.32. The company has a 50 day moving average of $76.14 and a two-hundred day moving average of $70.09. The company has a market capitalization of $3.23 billion, a price-to-earnings ratio of -19.54 and a beta of 1.84. Axsome Therapeutics has a 52-week low of $35.16 and a 52-week high of $91.29.

Institutional Investors Weigh In On Axsome Therapeutics

Several large investors have recently made changes to their positions in AXSM. China Universal Asset Management Co. Ltd. boosted its position in shares of Axsome Therapeutics by 33.6% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 589 shares of the company’s stock valued at $36,000 after acquiring an additional 148 shares during the last quarter. AQR Capital Management LLC increased its holdings in shares of Axsome Therapeutics by 1.7% during the first quarter. AQR Capital Management LLC now owns 8,825 shares of the company’s stock valued at $544,000 after acquiring an additional 148 shares in the last quarter. Victory Capital Management Inc. boosted its position in shares of Axsome Therapeutics by 5.1% during the first quarter. Victory Capital Management Inc. now owns 3,844 shares of the company’s stock valued at $237,000 after buying an additional 185 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in Axsome Therapeutics by 1.7% in the second quarter. Price T Rowe Associates Inc. MD now owns 14,627 shares of the company’s stock worth $560,000 after purchasing an additional 245 shares during the last quarter. Finally, Legal & General Group Plc lifted its position in shares of Axsome Therapeutics by 0.9% during the 4th quarter. Legal & General Group Plc now owns 27,011 shares of the company’s stock valued at $2,083,000 after buying an additional 250 shares in the last quarter. 72.70% of the stock is owned by hedge funds and other institutional investors.

Axsome Therapeutics Company Profile

(Get Free Report)

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.